drugset / Trial / NCT01256411

A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension

NCT01256411

Phase 2 Completed 341 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the long-term safety, tolerability and efficacy of LCZ696.

Timeline

Start
2010-11
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject LCZ696 Unknown 100 mg
Subject LCZ696 Unknown 200 mg
Subject LCZ696 Unknown 400 mg
Background Amlodipine Other / unclassified 5 mg
Background Amlodipine Other / unclassified 10 mg
Background Hydrochlorothiazide Unknown 12.5 mg
Background Hydrochlorothiazide Unknown 25 mg